The proto-oncogene product p53 was initially identified as a host cell protein bound to T antigen, the dominant transforming oncogene of the SV40 virus (Lane & Crawford, 1979) . It is a cellular protein expressed at low levels in non-transformed cells; however, elevated levels are found in certain tumours and in transformed cell lines (Dippold et al., 1981; Crawford et al., 1981; Iggo et al., 1990) . Normal levels of p53 act as tumour suppressor genes in murine model systems ; but mutations in the p53 have now been demonstrated in the murine gene and can convert it into a dominant gene .
Recently, p53 mutations have been demonstrated in several human tumours Cattoretti et al., 1988; Baker et al., 1989; Takahashi et al., 1989; Iggo et al., 1990; Chibia et al., 1990) . It is of particular interest that Iggo et al. (1990) demonstrated abnormal expression of p53 in lung tumours immunohistochemically and in at least three cases, the abnormal staining pattern arose in cells that had undergone p53 mutations. As the normal p53 protein has a very short half-life (6-20 min), it may be inferred that the detection of the p53 protien is synonymous with mutation because the mutant form has a half-life of up to 6 h, probably due to stabilisation of the protein (Lane & Benchimol, 1990) . In addition Iggo et al. (1990) Iggo et al., 1990; Harlow et al., 1985; Bartek et al., 1990; Takahashi et al., 1989 and Chiba et al. (1990) . Chiba et al. (1990) We have previously demonstrated that there is elevated expression of several oncogenes, (Ha-ras, Ki-ras, c-erbB-2 and c-myc) in the development of squamous cell carcinoma of the head and neck (Field et al., 1986 (Field et al., , 1987 (Field et al., , 1989 (Field et al., , 1990 Field, 1991) . We have reported a correlation between elevated c-myc oncoprotein expression and poor prognosis (Field et al., 1989) , but as yet there is no published evidence to demonstrate that amplification or point mutations of oncogenes are associated with the clinical outcome of these patients (Saranath, 1989; Rumsby et al., 1989; Sheng et al., 1990; Field et al., unpublished) . Parada et al. (1984) have previously reported co-operation between p53 tumour antigen and ras in cellular transformation. We have recently demonstrated that low levels of ras p21 expression correlate with the disease free survival in patients with SCC of the head and neck . Three per cent of the patients with ras negative staining were alive 60 months after diagnosis whereas 54% of the patients with positive staining were still alive after the same time period (P <0.01).
In this study we have investigated the levels of p53 expression in 73 head and neck squamous cell carcinomas using highly specific antibodies to p53, and we have correlated the results with the already known clinical and pathological prognostic factors, as well as the patients' smoking history. whereas 35 had previous treatment. The tissue sections were fixed in formalin and embedded in parffin wax. Serial sections of 5 Lm thickness were cut and processed for immunocytochemistry. The following clinical and pathological data were available: TNM staging using the UICC convention (UICC 1987), site of tumour, details of previous treatment, histopathological differentiation, the pathology of lymph node metastases and follow up. The smoking pattern was classified as non-smokers, moderate smokers (under 20 cigarettes per day) or heavy smokers (over 20 cigarettes per day) or equivalent quantities of pipe tobacco. Patients who had stopped smoking more than 5 years ago were considered separately.
P53-PAb421 and the p53-PAb18O1 antibodies were used for immunocytochemistry (Oncogene Science). P53-PAb421 reacts by immunoprecipitation with a 53 kD protein in a broad range of mammalian species including humans. PAb421 recognises a denaturation resistant epitope located between amino acids 370-378 of p53 (Harlow et al., 1981; Wade-Evans & Jenkins, 1985) . The p53 protein was first detected because of its ability to complex tightly with the small DNA tumour virus SV40 large T antigen. (Harlow et al., 1981) . As the PAb421 antibody has been reported to cross react with keratin (Harlow et al., 1985) we also used the p53-PAbl801 antibody on 40 specimens. This antibody reacts by immunoprecipitation with a 53 kD protein specifically with the p53 human gene product. PAbl801 *recognises a denaturation resistant epitope between amino acids 32 and 79 (Banks et al., 1986) . In this study PAb421 and PAb1801 were detected by means of the avidin-biotin peroxidase technique. Briefly, 5 gim sections were rehydrated through graded alcohol to water and rinsed in 10 mM Tris buffered saline (TBS) at pH 7.6. Endogenous peroxidase activity was eliminated by immersing the specimens for 20 min in acidified methanol containing 3% H202 and then washed in water. The avidin -biotin -peroxidase complex (ABC) method (Hsu et al., 1981) (Furth et al., 1982) .
Quantitative data were analysed by x2 or Fisher exact test and weighted logistic regression (Armitage & Berry, 1987) where appropriate.
Results
The 208F cell line showed negative staining with both the p53 PAb420 and PAbl8O1 antibodies, whereas both the MRSV3.1 cells immortalised with a retroviral vector carrying the SV40 large T antigen and the MCF-7 cell line showed nuclear staining (Figure la,b) . Seventy-three head and neck squamous cell carcinomas were investigated for elevated levels of p53 gene expression, 67% of the squamous cell carcinomas showed positive staining; 16% of these had intense staining whereas 51 % showed moderate staining. Twenty specimens were investigated with both of these antibodies and in all but two of the cases, similar staining patterns were seen.
The normal p53 protein is restricted to the cell nucleus, but we have found the p53 gene product in both the nucleus and in the cytoplasm of the head and neck squamous cell carcinomas. No p53 oncoprotein staining was seen in the adjacent normal tissues (Figure 2a,b,c,d ).
Twenty-five of the 38 previously untreated patients and 24 of the 35 previously treated patients had positive p53 staining. As this difference was not significant it was felt appropriate to group untreated and previously treated patients together. No correlations were found between positive p53 staining and site, TNM staging, histological differentiation or positive lymph nodes (data not included). Ras expression was investigated in 56 of these specimens but was not found to correlate with p53 expression in this study.
However when we analysed the patients smoking history with the presence of p53 staining; six of seven non-smokers were non-p53 expressers, whereas 29 of 37 heavy-smokers had positive p53 expression (P <0.005) (Table I) . However, there were a group of patients that were either moderate or heavy smokers who did not have any p53 expression. Nine of ten patients who had stopped smoking for 5 or more years (range 5-18 years) had positive p53 staining in their tumour specimens. In addition no significant difference in the staining pattern was seen between the patients who had stopped smoking and the patients with a history of heavy smoking (P <0.05) (Figure 3) . However there was a higher incidence of p53 staining in the heavy smokers (29 of 37) compared with the moderate smokers (ten out of 19)). No correlation was found between smoking and any of the clinicopathological parameters.
Discussion
The results of this study indicates that elevated p53 expression correlates with a history of heavy smoking in patients with head and neck squamous cell carcinoma.
The p53 protein has not been identified immunologically in the nucleus of normal cells, as its level is so low , whereas in tumour tissue and cell lines, high levels of the protein are found due to stabilisation of the protein (Finlay et al., 1988) . Cytoplasmic staining of the p53 gene product has been previously reported in small cell carcinomas of the lung using two monoclonal antibodies (PAb240 an JG8). Similarly in this investigation p53 staining has been found in the nucleus; a substantial amount was also observed in the cytoplasm using two p53 antibodies, PAb420 and PAbl80l.
Half of the patients presenting (to one of us, PMS) with squamous cell carcinoma of the head and neck over the last 26 years were aged over 60 (n = 3392, median age 61 years) and many of them have a long history of smoking. Thus these results would suggest that carcinogens in smoke cause a mutation in the p53 gene and may therefore be considered as a probable initiation event in the development of the cancer. In addition two of these patients gave up smoking over 18 years ago which would suggest that mutagen(s) in tobacco cause a p53 mutation relatively early in the smoking history of these patients and that further event(s) are required for the development of the neoplasia. There is overwhelming epidemiological evidence for a correlation between heavy smoking and lung cancer (Doll & Peto, 1976) . Also the incidence of head and neck cancer, and or oral cancer in particular appears to be directly related to tobacco use. Furthermore, the relative risk increases with duration and quantity smoked (Wynder & Stellman, 1977; Silverman & Griffith 1972; Stell, 1972; Schmidt & Popham, 1981; Myers & Suen, 1989) . This is the first report to date to demonstrate a correlation between heavy smoking and aberrant expression of a specific gene.
Our results and those of Iggo et al. (1989) and Chiba et al. (1990) indicate that there is a strong association between both p53 mutations and over-expression in smoking related cancers. We now plan to analyse p53 mutations in squamous cell carcinoma of the head and neck and correlate the results with our immunohistochemical data.
If these results are considered along the lines of the currently accepted model of p53 mode of action, it may be suggested that the carcinogens in smoke damage the p53 gene in such a way as to increase its expression, and it may be argued that there has been both a loss of suppressor gene function and a gain in the dominant transforming activity of p53. Furthermore, tumours with no p53 staining may contain either a normal p53 gene or have lost the expression of both alleles or may contain a level of p53 mutant which cannot be detected by p53 PAb421 of p53 PAbl801 antibodies on formalin fixed sections.
In the long term, if it is demonstrated that smokers with head and neck cancer have p53 mutations or p53 overexpression, it may be possible to develop an anti-p53 specific therapy for these patients.
